Molly Went

2 weeks ago | nature.com | Molly Went |Charlie Mills |Amit Sud |James Allan |Richard S. Houlston

AbstractAlthough treatment options for B-cell malignancies have expanded, many patients continue to face limited response rates, highlighting an urgent need for new therapeutic targets.

Oct 17, 2024 | nature.com | Molly Went |Jessica Hislop |Richard S. Houlston

Although acute myeloid leukaemia (AML) is one of the most common haematological malignancies in adults, its aetiological basis is poorly understood [1]. The only well recognised modifiable risk factors are smoking and exposure to benzene [2]. There is increasing evidence for the redox system playing a significant role in both the development and progression of AML [3].

Aug 4, 2024 | nature.com | Molly Went |Gísli H. Halldórsson |Andrea Gunnell |Philip J Law |Amit Sud |Gudmar Thorleifsson | +24 more

AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel.

Jul 15, 2024 | nature.com | Jessica Hislop |Molly Went |Charlie Mills |Amit Sud |Philip J Law

Clonal haematopoiesis, the clonal expansion of a blood stem cell and its progeny, is increasingly detectable with age in the blood of healthy individuals [1, 2]. Clonal haematopoiesis of indeterminate potential (CHIP) is characterised by the expansion of clones with oncogenic mutations, primarily in DNMT3A, TET2, ASXL1, JAK2, and is associated with mosaic chromosomal alterations [2].

Mar 25, 2024 | nature.com | Molly Went |Amit Sud |Charlie Mills |Philip J Law |Jayaram Vijayakrishnan |Ines Gockel | +5 more

AbstractFor many cancers there are only a few well-established risk factors. Here, we use summary data from genome-wide association studies (GWAS) in a Mendelian randomisation (MR) phenome-wide association study (PheWAS) to identify potentially causal relationships for over 3,000 traits. Our outcome datasets comprise 378,142 cases across breast, prostate, colorectal, lung, endometrial, oesophageal, renal, and ovarian cancers, as well as 485,715 controls.